Gabrielle Breugelmans | Director Of Research
Access to Medicine Foundation | Netherlands

Gabrielle Breugelmans, Director Of Research, Access to Medicine Foundation

Gabrielle Breugelmans joined the Access to Medicine Foundation in 2018 as Director of Research where is responsible for the direction and delivery of the Access to Medicine Foundation’s research programmes and other research activities. She is an infectious disease epidemiologist with broad expertise in global health, poverty-related diseases and vaccinology in low- to middle-income countries. She holds a PhD and Master of Public Health degree in Epidemiology from the Johns Hopkins Bloomberg School of Public Health in the U.S., and a Master’s degree in Health Sciences from the University of Maastricht in the Netherlands. Before joining the Access to Medicine Foundation, Gabrielle led the networking team at the European & Developing Countries Clinical Trials Partnership (EDCTP) in the Hague, the Netherlands, where she was responsible for identifying collaboration opportunities and creating partnerships with private- and public-sector organisations to accelerate the development of medical interventions against poverty-related diseases. She has also held various positions at the Agence de Médecine Préventive, a French NGO specialised in field-based vaccinology and epidemiology, and at Sanofi Pasteur MSD, where she oversaw the epidemiological programme for the quadrivalent human papillomavirus vaccine.

Appearances:



Oct 28th Pre-Congress Workshops @ 10:00

Workshop B: Vaccine Market Access and Regulatory Affairs

The market for vaccines is more complex than most and there are many definitions of what constitutes a healthy market – one that ensures sustainable, sufficient, relevant, predictable supply to meet demand. There are a complex, interconnected set of factors that together comprise the market place, including the regulatory environment, the incentives or disincentives for investing in new innovation and R&D, how the value of vaccines are assessed, the procurement of vaccines, as well as the infrastructure for delivery of and access to vaccines. How global, regional, and national stakeholders, including government authorities, multi-laterals, NGOs, and industry, make decisions and act in the marketplace can determine the health or the fragility of the vaccine market in the short and long-term. This session will explore what we mean by a healthy vaccine market, the various factors that comprise the market, and factors that can enable or impede a healthy market.
  • Overview of global vaccine market and describing the characteristics of a healthy market (review of current frameworks)
  • Insights from the introduction of new vaccines and strategies that have been leveraged to encourage sustainable, sufficient, relevant, predictable supply to meet demand – what’s worked and what hasn’t in different contexts, including LMICs
  • Opportunities for greater collaboration across stakeholders, including industry, to think holistically about vaccine markets and address key challenges that undermine the health of the market

Oct 29th Day 1 @ 14:45

Harmonising priorities in Europe: Role of public health, government strategies and industry to halting the AMR crisis – do we have a consistent message?

Insight and progress from international healthcare agencies; How can regulatory and access policies can be used to strengthen utilization of vaccines in our international action plans to address AMR?
last published: 19/Sep/19 13:06 GMT

back to speakers

Sign Up for Event Updates